https://scholars.lib.ntu.edu.tw/handle/123456789/582211| Title: | Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2005 update | Authors: | Liaw Y.-F. Leung N. Guan R. Lau G.K.K. Merican I. McCaughan G. Gane E. JIA-HORNG KAO Omata M. Chutaputti B.A. DING-SHINN CHEN Chien R.N. Cooksley G. Han K.H. Ichida T. Lai M.Y. Lesmana L. Piratvisuth T. Sarin S.K. Sollano J. Suh D.J. Yao G.B. Yeh C.T. Yokosuka O. |
Keywords: | Adefovir; Chronic hepatitis B; Hepatic decompensation; Interferon; Lamivudine; Liver transplantation | Issue Date: | 2005 | Journal Volume: | 25 | Journal Issue: | 3 | Start page/Pages: | 472-489 | Source: | Liver International | Abstract: | Background/Aims: A large amount of new data on the treatment of chronic hepatitis B has become available such that the 2003 consensus statement requires revision and update. Methods: New data were presented, discussed and debated in an expert pre-meeting to draft a revision. The revised contents were finalized after discussion in a general meeting of APASL. Results: Conceptual background, including the efficacy and safety profile of currently available and emerging drugs, was reviewed. Nineteen recommendations were formed and unresolved issues and areas for further study were suggested. Conclusion: The current therapy of chronic hepatitis B is modestly effective but not satisfactory. The development of new drugs and new strategies is required to further improve the outcomes of treatment. ? Blackwell Munksgaard 2005. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-20444363583&doi=10.1111%2fj.1478-3231.2005.01134.x&partnerID=40&md5=e0bb4ad41886fa707188928d099e2cef https://scholars.lib.ntu.edu.tw/handle/123456789/582211 |
ISSN: | 1478-3223 | DOI: | 10.1111/j.1478-3231.2005.01134.x | SDG/Keyword: | adefovir; adefovir dipivoxil; alanine aminotransferase; alpha interferon; clevudine; emtricitabine; entecavir; famciclovir; fialuridine; hepatitis B antibody; interleukin 12; lamivudine; lobucavir; peginterferon; peginterferon alpha2a; peginterferon alpha2b; ribavirin; telbivudine; tenofovir; thymosin; vidarabine; virus antigen; virus DNA; alanine aminotransferase blood level; antibiotic prophylaxis; antiviral activity; cancer chemotherapy; Chinese medicine; chronic hepatitis; clinical trial; comorbidity; depression; drug approval; drug dose regimen; drug efficacy; drug indication; drug mechanism; drug safety; drug substitution; fatigue; flu like syndrome; hepatitis B; Hepatitis B virus; hepatitis C; human; Human immunodeficiency virus infection; immunological tolerance; infection control; liver cirrhosis; liver transplantation; neutropenia; outcomes research; pathogenesis; patient care; patient monitoring; patient satisfaction; practice guideline; pregnancy; review; risk benefit analysis; thrombocytopenia; virus replication; Antiviral Agents; Asia; Australia; Hepatitis B, Chronic; Humans; New Zealand; Pacific Islands; Practice Guidelines [SDGs]SDG3 |
| Appears in Collections: | 臨床醫學研究所 |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.